Expertise in
6
conditions

Dr. Mazen Khalil

Interventional Cardiology
Memorial Health University Physicians Heart Care - Waters Avenue
4700 Waters Ave Bldg 100 Ste 400, 
Savannah, GA 
Offers Telehealth
Expertise in
6
conditions
Memorial Health University Physicians Heart Care - Waters Avenue
4700 Waters Ave Bldg 100 Ste 400, 
Savannah, GA 

Overview

Mazen Khalil is an Interventional Cardiologist in Savannah, Georgia. Dr. Khalil is highly rated in 6 conditions, according to our data. His top areas of expertise are Heart Attack, Apoplexy, Angina, Pacemaker Implantation, and Percutaneous Coronary Intervention (PCI).

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Interventional Cardiology

Licenses

Internal Medicine in SC

Hospital Affiliations

Savannah Health Services LLC Dba Memorial Health University Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Memorial Health University Physicians Heart Care - Waters Avenue
4700 Waters Ave Bldg 100 Ste 400, Savannah, GA 31404
Other Locations
Memorial Health University Physicians Heart Care - Jesup
131 Peachtree St, Jesup, GA 31545

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Enrollment Status: Active_not_recruiting
Publish Date: April 01, 2026
Intervention Type: Drug, Other
Study Drug: Ribociclib
Study Phase: Phase 3
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

9 Total Publications

Peripheral Vascular Intervention Training-Gaps and Solutions.
Peripheral Vascular Intervention Training-Gaps and Solutions.
Journal: Journal of the Society for Cardiovascular Angiography & Interventions
Published: August 22, 2023
Similar Doctors
Expertise in
31
conditions
Dr. Stuart Smalheiser
Interventional Cardiology
Expertise in
31
conditions
Dr. Stuart Smalheiser
Interventional Cardiology

Beaufort Memorial Heart Specialists

300 Midtown Dr, 
Beaufort, SC 
 (32.1 miles away)
843-770-4550
Languages Spoken:
English
See accepted insurances

Stuart Smalheiser is an Interventional Cardiologist in Beaufort, South Carolina. Dr. Smalheiser is highly rated in 31 conditions, according to our data. His top areas of expertise are Coronary Heart Disease, Atherosclerosis, Angina, Arrhythmias, and Pacemaker Implantation.

Expertise in
53
conditions
Dr. Michael Babcock
Interventional Cardiology
Expertise in
53
conditions
Dr. Michael Babcock
Interventional Cardiology

St. Joseph's/Candler Physician Network Cardiology Associates Of Savannah

11700 Mercy Blvd Ste 6, 
Savannah,, GA 
 (8.5 miles away)
912-927-3434
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Babcock is an Interventional Cardiologist in Savannah,, Georgia. Dr. Babcock is highly rated in 53 conditions, according to our data. His top areas of expertise are Coronary Heart Disease, Aortic Valve Stenosis, Fainting, Aortic Valve Replacement, and Transcatheter Aortic Valve Replacement (TAVR).

Expertise in
25
conditions
Dr. Chadwick Huggins
Interventional Cardiology
Expertise in
25
conditions
Dr. Chadwick Huggins
Interventional Cardiology

Memorial Health University Physicians Heart Care-Waters Avenue

4700 Waters Ave Bldg 100 Ste 400, 
Savannah, GA 
 (2.9 miles away)
912-273-1100
Languages Spoken:
English
See accepted insurances

Chadwick Huggins is an Interventional Cardiologist in Savannah, Georgia. Dr. Huggins is highly rated in 25 conditions, according to our data. His top areas of expertise are Atrial Fibrillation, Pulmonary Veno-Occlusive Disease, Pulmonary Hypertension, and Angina.

Frequently Asked Questions about Dr. Mazen Khalil

Is Dr. Mazen Khalil a top-rated expert for Heart Attack?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mazen Khalil is classified as an Advanced expert for Heart Attack, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mazen Khalil specialize in?

While Dr. Mazen Khalil is a Interventional Cardiology, they have specific expertise in Heart Attack, Apoplexy, and Angina. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Interventional Cardiology.

Does Dr. Mazen Khalil participate in research or clinical trials?

Yes. Dr. Mazen Khalil has published 9 articles and abstracts on conditions like Heart Attack. You can view a list of Dr. Mazen Khalil's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mazen Khalil accept my insurance?

Dr. Mazen Khalil accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Khalil's expertise for a condition
ConditionClose
      View All 33 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile